TABLE 3.

Univariate and multivariate analysis of factors predicting microbiological failure at month 1 from the initiation of therapy with oral fosfomycin (n = 137)

Factora	Value		P value	Univariateb		Multivariatec
	Microbiological cure (n = 82)	Microbiological failure (n = 55)		OR	95% CI	OR	95% CI	P value
Age at diagnosis of AB (yrs) (mean ± SD)	55.3 ± 12.9	56.6 ± 14.6	0.362
Female gender (n [%])	44 (53.7)	35 (66.0)	0.154
Time interval from transplantation to diagnosis of AB (mo) (median [IQR])	3.9 (1.2–16.9)	3.2 (1.3–11.1)	0.986
Previous kidney transplantation (n [%])	13 (15.9)	9 (16.4)	0.936
Diabetic nephropathy (n [%])	15 (18.3)	9 (16.4)	0.771
Polycystic kidney disease [(n [%])	14 (17.1)	9 (16.4)	0.913
Previous UTI (n [%])d	30 (36.6)	32 (58.2)	0.013	2.92	1.39–6.12	2.42	1.11–5.29	0.027
Anatomical abnormality of the urinary tract (n [%])	19 (23.2)	12 (21.8)	0.853
Double-J ureteral stenting (n [%])	15 (18.3)	11 (20.0)	0.803
Indwelling urinary catheter (n [%])	6 (7.3)	2 (3.6)	0.475
Percutaneous nephrostomy (n [%])	5 (6.1)	1 (1.8)	0.401
Daily corticosteroid dose (mg) (median [IQR])	10 (5–20)	8.8 (5–10)	0.130
eGFR at diagnosis (ml/min) (mean ± SD)	42.9 ± 19.3	42.7 ± 22.5	0.956
Trometamol fosfomycin (n [%])	46 (56.1)	26 (47.3)	0.311
Salvage therapy (n [%])	2 (2.4)	13 (23.6)	0.000	10.92	2.33–51.31	8.31	1.67–41.35	0.010
Multidrug-resistant isolate (n [%])	45 (58.4)	33 (61.1)	0.759
ESBL-producing isolate (n [%])	12 (14.6)	16 (29.1)	0.040	2.12	0.89–5.02
Carbapenem-resistant isolate (n [%])	4 (4.9)	0 (0.0)	0.149
Daily fosfomycin dose (g) (median [IQR])	3 (1.5–3)	3 (1.5–3)	0.494
Duration of therapy (days) (median [IQR])	3 (2–7)	3 (2–10)	0.636

^aAB, asymptomatic bacteriuria; eGFR, estimated glomerular filtration rate; ESBL, extended-spectrum β-lactamase; IQR, interquartile range; UTI, urinary tract infection.

^bOR, odds ratio; CI, confidence interval.

^cHosmer-Lemeshow P value = 0.781.

^dWithin the previous 3 months.